Javascript is not enabled on this browser. This site will not work properly without Javascript.
 |
In vivo Characterization |
 |
| Methods used to characterize site in vivo: |
[32P] bio-synthetic labeling (15), flow cytometry (14), immunoprecipitation (14), mass spectrometry (8, 9, 10, 11), mutation of modification site (7, 13, 14, 15), phospho-antibody (6, 12, 13, 14, 15), western blotting (6, 12, 14)
|
| Relevant cell line - cell type - tissue: |
32D (myeloid) (14), BaF3 ('B lymphocyte, precursor') (7, 13), COS (fibroblast) (15), IC2 (mast) (12), mast-bone marrow (7), mast-bone marrow [PTPRA (mouse), homozygous knockout] (6)
|
|
|
1
|
Liu S, et al. (2010) Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 17, 333-47
20385359
Curated Info
|
|
2
|
(2010) CST Curation Set: 9105; Year: 2010; Biosample: F9; Disease: testicular cancer; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info
|
|
3
|
(2010) CST Curation Set: 9104; Year: 2010; Biosample: ES J1; Disease: -; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info
|
|
4
|
(2010) CST Curation Set: 9109; Year: 2010; Biosample: P19; Disease: testicular cancer; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info
|
|
5
|
(2010) CST Curation Set: 9108; Year: 2010; Biosample: PY2; Disease: -; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info
|
|
6
|
Samayawardhena LA, Pallen CJ (2008) Protein-tyrosine phosphatase alpha regulates stem cell factor-dependent c-Kit activation and migration of mast cells. J Biol Chem 283, 29175-85
18725415
Curated Info
|
|
7
|
Yu M, et al. (2006) The scaffolding adapter Gab2, via Shp-2, regulates kit-evoked mast cell proliferation by activating the Rac/JNK pathway. J Biol Chem 281, 28615-26
16873377
Curated Info
|
|
8
|
(2006) CST Curation Set: 1516; Year: 2006; Biosample: Thom; Disease: -; Treatment: serum starved; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info
|
|
9
|
(2006) CST Curation Set: 1517; Year: 2006; Biosample: Thom; Disease: -; Treatment: serum starved; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info
|
|
10
|
(2006) CST Curation Set: 1518; Year: 2006; Biosample: Thom; Disease: -; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info
|
|
11
|
(2006) CST Curation Set: 1519; Year: 2006; Biosample: Thom; Disease: -; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info
|
|
12
|
Shivakrupa R, Bernstein A, Watring N, Linnekin D (2003) Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant. Cancer Res 63, 4412-9
12907613
Curated Info
|
|
13
|
Hashimoto K, et al. (2003) Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation. Blood 101, 1094-102
12393643
Curated Info
|
|
14
|
Gommerman JL, et al. (2000) Differential stimulation of c-Kit mutants by membrane-bound and soluble Steel Factor correlates with leukemic potential. Blood 96, 3734-42
11090054
Curated Info
|
|
15
|
Serve H, Hsu YC, Besmer P (1994) Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells. J Biol Chem 269, 6026-30
7509796
Curated Info
|
